---

Triple Negative Breast Cancer (TNBC): Molecular Classification, Prognostic Markers, and IHC/Laboratory Tests

---

1. Overview of Breast Cancer Molecular Classification

The Three Major Clinical Groups

---

2. Intrinsic ("Six Major") Molecular Subtypes by Gene Expression Profiling

"A useful molecular classification system that better reflects the spectrum of breast cancer biology and behavior separates breast cancers into six major 'intrinsic' subtypes based on gene expression profiling; luminal A, luminal B, HER2 enriched, basal-like, normal-like, and claudin-low."

• Robbins, Cotran & Kumar Pathologic Basis of Disease

---

3. Triple Negative Breast Cancer (TNBC) - In Depth

Definition

Key Epidemiological Features

• More common in younger women and African American women
• Strongly associated with germline BRCA1 mutations (~20% of TNBC patients have a pathogenic BRCA variant)
• BRCA1/2 mutation carriers should be tested (germline sequencing) because they may be eligible for PARP inhibitors

TNBC and Basal-like Subtype

• TNBC and the "basal-like" intrinsic subtype strongly overlap but are not identical (~80% of TNBC are basal-like; ~85% of basal-like are TNBC)
• Basal-like tumors additionally express basal cytokeratins (CK5/6, CK14, CK17) and EGFR
• The term "basal-like" comes from the resemblance to myoepithelial/basal cells of the normal breast

Lehmann Subtypes (Further TNBC Subclassification)

Prognosis of TNBC

• Worst overall prognosis among the three groups
• Highest risk of developing early metastases and death despite treatment
• No endocrine therapy option (ER-negative)
• No HER2-targeted therapy applicable
• Key advances: pembrolizumab (PD-1 checkpoint inhibitor) + chemotherapy showed markedly improved outcomes in early TNBC (KEYNOTE-522 trial, 2022)
• PARP inhibitors (olaparib, talazoparib) for BRCA1/2-mutated metastatic TNBC

---

4. Prognostic and Predictive Markers in Breast Cancer

A. Standard IHC Panel (Mandatory for All Invasive Breast Cancers)

B. Histological Grade (Nottingham Grade / Elston-Ellis System)

1. Tubule formation (gland formation)
2. Nuclear pleomorphism
3. Mitotic count

C. Staging Markers (Anatomic + Biologic - AJCC 8th Edition)

• Tumor size (T): pT1-4
• Node status (N): pN0-3 (sentinel lymph node biopsy / ALND)
• Distant metastasis (M)
• The 8th AJCC edition now incorporates biomarker groups (ER, PR, HER2, grade) into the prognostic stage groups

D. Multi-Gene Expression Assays (Genomic Tests)

"Ki-67 was included with three other widely measured breast cancer markers (ER, PR, and HER2) into a panel of four immunohistochemical makers (IHC4), which together provided similar prognostic information."

• Schwartz's Principles of Surgery, 11th ed.

"Prosigna outperformed other assays in direct comparison of six prognostic signatures." - Fischer's Mastery of Surgery, 8th ed.

---

5. Additional/Emerging Markers in Breast Carcinoma

Genetic/Hereditary Markers

Immunotherapy Markers

Other Markers

---

6. Summary: TNBC vs Other Subtypes at a Glance

Prognosis (best → worst):
Luminal A  →  Luminal B  →  HER2  →  TNBC

• TNBC has no targeted therapy from standard ER/HER2 axis
• Treatment backbone = neoadjuvant chemotherapy (anthracycline + taxane) ± carboplatin
• Pembrolizumab (anti-PD-1) is now standard in early-stage TNBC (CPS-unselected)
• PARP inhibitors for BRCA1/2-mutated TNBC
• Sacituzumab govitecan (anti-Trop-2 ADC) for metastatic TNBC

---

• Robbins & Kumar Basic Pathology (Table 17.7, p. 709-710) - major subtype comparison table
• Robbins, Cotran & Kumar Pathologic Basis of Disease - six intrinsic subtypes; BRCA genetics; breast cancer evolution model
• Fischer's Mastery of Surgery, 8th ed. (p. 1780-1781) - clinical classification table with Ki-67
• Sabiston Textbook of Surgery - molecular markers, Oncotype DX, MammaPrint, PAM50
• Chen et al., 2025 - "Classifications of TNBC: insights and current therapeutic approaches" (PMID: 39893480)
• Varzaru et al., 2024 - "TNBC: Molecular Particularities Still a Challenge" (PMID: 39272660)

---

Breast Carcinoma: Clinical Features, Molecular Classification, Prognostic Markers, and IHC Tests

(Structured for a 10-Mark Answer)

---

I. CLINICAL FEATURES OF BREAST CARCINOMA

A. Local Breast Symptoms

• In unscreened populations (including young women), most cancers present as a palpable mass, typically at least 2-3 cm at the time of detection
• Location: upper outer quadrant is the most common site (~50%), followed by the central portion (~20%)
• Character: hard, irregular, non-tender, ill-defined margins (due to desmoplastic stromal reaction)
• Produces a grating sound on cutting due to chalky-white desmoplastic stroma
• In screened older populations, ~60% are detected before symptoms develop; ~20% are in situ carcinomas

• Skin dimpling/retraction - invasion of Cooper's ligaments tethers the skin
• Peau d'orange ("orange peel skin") - blockage of dermal lymphatics causes skin edema; the edematous skin is tethered by Cooper's ligaments, mimicking an orange peel surface

• Skin ulceration - in advanced/locally advanced disease
• Skin fixation/satellite nodules - in very advanced disease

• Nipple retraction/inversion - when the central breast is involved, retraction develops
• Paget disease of the nipple - DCIS extending up the lactiferous ducts into the nipple skin produces a unilateral crusting/eczematous exudate over the nipple and areola; associated with an underlying invasive carcinoma in many cases
• Nipple discharge (bloody/serous)

B. Regional (Nodal) Features

• Axillary lymph node enlargement - most common first site of metastasis
• Lymphatic drainage flows to sentinel lymph nodes in the axilla; if positive, remaining nodes may be involved
• In unscreened populations, at least 50% already have lymph node spread at presentation
• In inflammatory breast cancer: >75% have palpable axillary lymphadenopathy at presentation
• Rare: supraclavicular or internal mammary node involvement

C. Inflammatory Breast Carcinoma (Special Presentation)

• Brawny induration, diffuse erythema with a raised edge
• Skin edema (peau d'orange)
• No discrete palpable mass - diffusely infiltrative
• Caused by extensive plugging of dermal lymphovascular spaces by tumor cells
• Note: the name "inflammatory" is a misnomer - there is no true inflammation histologically
• Often confused with bacterial mastitis, leading to delayed diagnosis
• Tumor is usually high-grade, may be luminal, HER2+, or triple-negative

D. Distant Metastasis Features

• Lobular carcinoma has unique spread: cerebrospinal fluid, serosal surfaces, GI tract, ovary, uterus, bone marrow

E. Screening-Detected vs. Symptomatic Presentation

---

II. MOLECULAR CLASSIFICATION OF BREAST CANCER

Three Major Clinical Groups (by IHC)

Six Intrinsic Subtypes (by Gene Expression Profiling)

---

III. TRIPLE NEGATIVE BREAST CANCER (TNBC) - DETAILED

• Highest risk of early metastasis and death
• Early relapse peak: <8 years; late recurrence rare
• No ER-targeted or HER2-targeted therapy applicable
• Key somatic mutations: TP53 (70-80%), PIK3CA (9%)

---

IV. PROGNOSTIC MARKERS IN BREAST CARCINOMA

A. Anatomic/Histologic Prognostic Factors

B. Biological/Molecular Prognostic Factors

C. Genomic/Multi-gene Assays (Prognostic)

---

V. IHC AND LABORATORY TESTS FOR BREAST CARCINOMA

Standard Mandatory Panel (All Invasive Cancers)

Additional Diagnostic IHC Markers

Immunotherapy Biomarkers

Genetic Tests

---

VI. STAGING - AJCC 8th Edition (Integrates Biology + Anatomy)

• T (tumor size/extent) + N (nodal status) + M (metastasis) = Anatomic Stage
• Prognostic Stage then adds: histologic grade + ER + PR + HER2 + multigene assay results
• TNBC is "up-staged" in prognostic staging to reflect aggressive biology
• Luminal A cancers are "down-staged" to reflect favorable biology
• Inflammatory carcinoma = clinical Stage III regardless of T/N

---

QUICK SUMMARY TABLE FOR EXAM

Prognosis (Best → Worst):
  Luminal A → Luminal B → HER2 → TNBC (Basal-like)

TNBC Key Points:
  • Definition: ER-/PR-/HER2-
  • ~15% of all breast cancers
  • Grade 3; BRCA1 association; African American women
  • No endocrine or HER2 targeted therapy
  • Treatment: Chemo (anthracycline + taxane ± carboplatin)
             + Pembrolizumab (early TNBC, KEYNOTE-522)
             + PARP inhibitors (if BRCA1/2 mutated)
             + Sacituzumab govitecan (metastatic)
  • Early relapse (<8 yrs); brain/visceral metastases

IHC Panel: ER + PR + HER2 (± FISH) + Ki-67 + Grade
Genomic: Oncotype DX / MammaPrint / PAM50 (ER+ only)
Genetic: BRCA1/2 testing for all TNBC patients

---

Breast Carcinoma: Complete 10-Mark Answer

Etiology, Pathogenesis, Clinical Features, Molecular Classification, Prognostic Markers, and IHC/Laboratory Tests

---

I. ETIOLOGY AND RISK FACTORS

High Penetrance (Relative Risk > 4.0)

• Female sex (99% of cases are female)
• Increasing age (rare <25 years; sharp rise after age 30)
• Germline mutations of high penetrance (BRCA1, BRCA2, TP53, PTEN)
• Strong family history (>1 first-degree relative, young age of onset, multiple cancers)
• Personal history of breast cancer
• High breast density on mammography

Moderate Penetrance (Relative Risk 2.1-4.0)

• Germline mutations of moderate penetrance (ATM, CHEK2, PALB2)
• High-dose radiation to the chest at a young age (e.g., treatment for lymphoma)
• Family history in one first-degree relative

Low Penetrance (Relative Risk 1.1-2.0)

• Early menarche (age <12 years) - increased lifetime estrogen exposure
• Late menopause (age >55 years) - same
• Late first pregnancy (age >35 years) or nulliparity
• Absence of breastfeeding
• Exogenous hormone therapy (combined OCP/HRT)
• Postmenopausal obesity (adipose tissue produces estrogen)
• Physical inactivity
• High alcohol consumption

Protective factors: Early pregnancy (before age 20), prolonged breastfeeding

Hereditary Susceptibility Genes (Key Table)

---

II. PATHOGENESIS

A. General Concept

B. Low-Grade Pathway (ER-Positive / Luminal)

• Proceeds through recognizable ER-positive precursor lesions: Normal breast → Flat epithelial atypia (columnar cell lesions) → Atypical ductal hyperplasia (ADH) → Low-grade DCIS → Invasive ER-positive carcinoma (Luminal A)
• Key genetic changes: loss of 16q, gain of 1q, PIK3CA mutations
• Result: Well-differentiated, slow-growing, ER-positive tumors
• Associated with germline BRCA2 mutations in familial cases

C. High-Grade Pathway (TNBC / HER2)

• Precursor lesion is high-grade DCIS; earliest steps are unidentified
• Key genetic changes: TP53 mutations, BRCA1 inactivation, increased genomic instability, HER2 amplification (17q12), loss of 13q, gain of 11q13
• Results in: HER2+ tumors, Luminal B, or Triple-negative tumors
• Associated with germline BRCA1 mutations (→ TNBC) and TP53 mutations (→ HER2+)

D. TNBC/Basal-like Specific Pathogenesis

• Loss of BRCA1 function impairs differentiation of ER-negative progenitor cells to ER-positive luminal cells → accumulation of genomically unstable ER-negative progenitors
• TP53 mutation: found in ~70-80% of TNBC somatic cases
• Cancers are ER-negative, HER2-negative with high genomic instability (chromosomal rearrangements, copy number changes)
• These tumors have homologous recombination deficiency (HRD) → susceptibility to PARP inhibitors (synthetic lethality)

E. Role of Estrogen in Pathogenesis

• Estrogen promotes proliferation of luminal breast epithelial cells → increases the number of cell divisions → higher probability of acquiring somatic mutations
• Estrogen may facilitate survival of BRCA1-deficient cells
• This explains why increased estrogen exposure (early menarche, late menopause, nulliparity, HRT, obesity) increases breast cancer risk - especially Luminal cancers

F. Tumor Microenvironment

• Cancer-associated fibroblasts: facilitate cell adhesion, ECM remodeling, immunosuppression
• Myoepithelial cells: their reduction creates gaps in the basement membrane, setting the stage for stromal invasion
• PD-L1 upregulation: tumor cells suppress host immune response via immune checkpoint proteins
• Tumor-infiltrating lymphocytes (TILs): paradoxically, high TILs in TNBC/HER2+ cancers indicate better prognosis and predict response to immunotherapy

G. In Situ → Invasive Transition

• Most genomic driver mutations present in invasive cancer are already present in in situ (DCIS) precursors
• The transition from in situ to invasive likely depends on tumor microenvironment changes (not new tumor cell mutations)

---

III. CLINICAL FEATURES

A. Local Breast Findings

B. Nodal/Systemic Features

• Axillary lymphadenopathy: first/most common metastatic site; hard, matted nodes
• Supraclavicular nodes (N3 disease)
• Lymph node spread: In unscreened populations, >50% already have node involvement at presentation; in screened populations, only ~15%

C. Inflammatory Breast Carcinoma (Special Clinical Syndrome)

• Stage IIIB; <3% of all breast cancers
• Brawny erythema with raised edges + skin edema (peau d'orange) over >33% of breast skin
• No discrete palpable mass - diffusely infiltrative
• Caused by plugging of dermal lymphovascular spaces by tumor cells (not true inflammation)

• 75% have palpable axillary lymphadenopathy; 25% have distant metastases at diagnosis

• Frequently misdiagnosed as bacterial mastitis

D. Screening vs Symptomatic Presentation

E. Metastatic Disease - Subtype-Specific Patterns

---

IV. MOLECULAR CLASSIFICATION

Three Major Clinical Groups (IHC-Based)

Six Intrinsic Subtypes (Gene Expression Profiling)

TNBC Deep Classification (Lehmann Subtypes)

---

V. PROGNOSTIC AND PREDICTIVE MARKERS

A. Anatomic/Histologic

B. Biological Markers

C. Multi-Gene Genomic Assays (ER+ only)

---

VI. IHC AND LABORATORY TESTS

Standard Mandatory IHC Panel (all invasive breast cancers)

Additional Diagnostic/Subtype IHC

Immunotherapy Biomarkers

Genetic/Molecular Tests

---

VII. STAGING (AJCC 8th Edition)

• Anatomic Stage: T (tumor) + N (nodes) + M (metastasis)
• Prognostic Stage: Anatomic stage adjusted by Grade + ER + PR + HER2 + multigene assay
• TNBC is "up-staged" to reflect its aggressive biology
• Luminal A is "down-staged" to reflect its favorable biology
• Inflammatory carcinoma = Stage III regardless of T/N

---

EXAM QUICK-RECALL SUMMARY

ETIOLOGY KEY POINTS:
  • Most important risk factors: Sex (female), Age, Estrogen exposure, Genetics
  • BRCA1 mutation → TNBC; BRCA2 mutation → ER+ Luminal
  • Protective: Early pregnancy (<20 yrs), prolonged breastfeeding

PATHOGENESIS PATHWAYS:
  Low-grade: PIK3CA mutation → Flat atypia → ADH → low-grade DCIS → LUMINAL A
  High-grade: TP53 + HER2 amplification → DCIS → HER2+
  DNA damage: BRCA1 inactivation + TP53 mutation → DCIS → TRIPLE NEGATIVE

CLINICAL FEATURES (remember "SNIP-LAMP"):
  Skin dimpling, Nipple retraction/Paget disease, Inflammatory signs (peau d'orange)
  Palpable lump (UOQ most common), Axillary lymphadenopathy, Metastases, Peau d'orange

MOLECULAR SUBTYPE PROGNOSIS (best → worst):
  Luminal A → Luminal B → HER2 → TNBC

TNBC TREATMENT:
  Chemo (anthracycline + taxane ± carboplatin)
  + Pembrolizumab (early TNBC, CPS-unselected - KEYNOTE-522)
  + PARP inhibitors (BRCA1/2 mutated)
  + Sacituzumab govitecan (metastatic)

IHC PANEL: ER + PR + HER2 (± FISH) + Ki-67 + Grade
GENETIC: BRCA1/2 testing for ALL TNBC

---

• Robbins & Kumar Basic Pathology, 10th ed. (Chapter 17 - Breast, pp. 709-713, Tables 17.7-17.9, Figs 17.28-17.30)
• Robbins, Cotran & Kumar Pathologic Basis of Disease, 10th ed. (Chapter 23 - Breast, pp. 954-966, Figs 23.15-23.17)
• Fischer's Mastery of Surgery, 8th ed. (pp. 1779-1781, Table 66.2)
• Schwartz's Principles of Surgery, 11th ed. (Chapter 17)
• Chen et al., 2025 - Classifications of TNBC (PMID: 39893480)